In this article, we will list the 5 Most Profitable Value Stocks to Buy Right Now. Please visit 7 Most Profitable Value Stocks to Buy Right Now to see the extended list and the methodology behind it.
5. National Grid (NYSE:NGG)
National Grid (NYSE:NGG) is one of the most profitable value stocks to buy right now. On March 25, GridCARE and National Grid announced a collaboration to accelerate the connection of large-load customers, such as data centers and manufacturers, to the power grid. By using the AI-driven GridCARE Energize platform, the partnership aims to identify underutilized capacity within existing infrastructure, particularly in New York. This approach targets reducing traditional interconnection delays from several years to as little as 6 to 12 months without compromising grid reliability.
The tech uses GenAI and physics-based simulations to evaluate quadrillions of operating scenarios, identifying specific conditions where the grid is underused. By integrating operational strategies like battery storage and distributed energy assets, the platform unlocks hidden megawatts from assets that currently operate at roughly one-third utilization. This strategy allows utilities to deliver power to high-demand AI and industrial projects using infrastructure that is already built and paid for.
The initiative is designed to support economic growth while protecting customer affordability by spreading fixed network costs across a broader load base. GridCARE, founded at Stanford’s Doerr School, has reportedly unlocked over $10 billion in economic value to date by bringing hundreds of megawatts of power online years ahead of traditional schedules.
National Grid (NYSE:NGG) is a utilities company that transmits and distributes electricity and gas. The company has several segments: UK Electricity Transmission, UK Electricity Distribution, New England, New York, National Grid Ventures, and Other.
4. Amgen Inc. (NASDAQ:AMGN)
Amgen Inc. (NASDAQ:AMGN) is one of the most profitable value stocks to buy right now. On April 6, Amgen announced positive topline results from a Phase 3 trial evaluating a subcutaneous formulation of TEPEZZA for patients with moderate-to-severe active Thyroid Eye Disease. The study used an on-body injector to deliver the medicine every two weeks, demonstrating efficacy comparable to the currently approved intravenous/IV version.
The trial successfully met its primary endpoint, with 77% of participants achieving a significant proptosis response (a reduction in eye bulging) compared to ~20% in the placebo group. The secondary endpoints also showed clinically meaningful improvements, including a mean proptosis reduction of 3.17 mm at week 24 and enhanced quality-of-life scores. Other benefits included positive responses in diplopia (double vision) and clinical activity scores.
Amgen Inc. (NASDAQ:AMGN) leadership noted that this subcutaneous option could evolve the standard of care by offering a more convenient and accessible delivery method for the 25,000+ patients who have historically relied on IV infusions. The safety profile for the subcutaneous administration was generally consistent with the established IV profile, with the addition of mild-to-moderate injection site reactions.
Amgen Inc. (NASDAQ:AMGN) is a drug manufacturer that delivers human therapeutics through pharmaceutical wholesale distributors. The company was founded in 1980 and is headquartered in California.
3. Gilead Sciences Inc. (NASDAQ:GILD)
Gilead Sciences Inc. (NASDAQ:GILD) is one of the most profitable value stocks to buy right now. On April 7, Gilead Sciences announced its agreement to acquire Germany-based Tubulis GmbH for up to $5 billion. This transaction includes an upfront cash payment of $3.15 billion, with an additional $1.85 billion contingent on the achievement of specific milestones. This acquisition is part of a broader effort by Gilead to support its oncology pipeline as it faces declining sales of its COVID-19 treatment, Veklury, and looming patent expiries on other key products.
Through this deal, Gilead gains access to Tubulis’ portfolio of guided missiles, scientifically known as antibody-drug conjugates/ADCs. These experimental cancer treatments are designed to deliver chemotherapy directly to malignant cells, thereby minimizing damage to healthy tissue and reducing side effects. This move follows other recent high-value acquisitions, including the $7.8 billion purchase of Arcellx in February and the $2 billion acquisition of Ouro Medicines in March, as Gilead pivots toward high-growth areas like cancer and immune disorder treatments.
The acquisition reflects a continuing spree of deal-making intended to transform Gilead beyond its traditional dominance in virology. By integrating Tubulis’ ADC platform, Gilead Sciences Inc. (NASDAQ:GILD) aims to strengthen its position in the competitive oncology market. This investment aligns with the company’s recent history of aggressive expansion into cell therapy and precision medicine to secure long-term revenue streams in the face of shifting market dynamics.
Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19.
2. AT&T Inc. (NYSE:T)
AT&T Inc. (NYSE:T) is one of the most profitable value stocks to buy right now. On March 31, AT&T reached a $2 billion agreement to enhance FirstNet, the federal emergency cellular network. Under the terms of the deal, the telecommunications giant will invest ~$1 billion directly into improving the program’s infrastructure. The remaining $1 billion in value will be delivered through significant cost savings for the program via reduced service rates for users.
This strategic update was facilitated by a 2025 executive order from President Donald Trump, which directed federal agencies to review all existing contracts for efficiency. The FirstNet system was originally awarded to AT&T Inc. (NYSE:T) in 2017 as part of a 25-year contract, following recommendations made after the 9/11 attacks to establish a dedicated communication line for first responders.
Currently, FirstNet is utilized by 31,000 US agencies, providing a unified network for police, firefighters, and medical personnel. AT&T’s President of Public Sector, Wes Anderson, emphasized that the agreement reflects the company’s commitment to the public-private partnership. The investment aims to ensure that the mission-critical network remains technologically advanced while lowering the financial burden on the government.
AT&T Inc. (NYSE:T) is a telecom and tech services company that operates through the Communications and Latin America segments. The Communications segment offers wireline telecom, wireless, and broadband services in the US and globally, while the Latin America segment manages services in Mexico.
1. HSBC Holdings (NYSE:HSBC)
HSBC Holdings (NYSE:HSBC) is one of the most profitable value stocks to buy right now. On March 23, HSBC appointed David Rice as its first Chief AI Officer, a newly created role aimed at integrating GenAI across the bank’s global operations. Rice previously served as the Chief Operating Officer for HSBC’s Corporate and Institutional Banking division. While many global banks include AI oversight within the broader responsibilities of a Chief Technology Officer, HSBC’s decision to establish a dedicated head for this technology marks a distinct shift in its leadership structure.
CEO Georges Elhedery has identified AI as a primary driver for the bank’s strategic goals, specifically targeting a return on tangible equity of over 17% for the 2026–2028 period. During a February 25 conference call, Elhedery informed investors that GenAI represents the bank’s largest current technology investment. The initiative focuses on automating and streamlining internal processes, mirroring a wider industry trend where financial institutions are utilizing AI to enhance coding, fraud detection, and credit application workflows.
The push for increased automation is closely tied to cost-cutting efforts, though the bank has not yet confirmed specific figures regarding potential workforce reductions. While HSBC Holdings (NYSE:HSBC) has not officially disclosed job cuts, reports earlier this month suggested that up to 20,000 roles could eventually be affected as AI capabilities expand. The bank maintains that these plans are in the early stages and that no final decisions regarding personnel have been made.
HSBC Holdings (NYSE:HSBC) is a financial services company that provides banking & financial products and services globally through its Wealth & Personal Banking, Commercial Banking, and Global Banking & Markets segments.
While we acknowledge the potential of HSBC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than HSBC and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
